A5005003137- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Bladder and Urothelial Cancer Treatments
- Immunotherapy and Immune Responses
- Ferroptosis and cancer prognosis
- Mathematical Biology Tumor Growth
- Prostate Cancer Treatment and Research
- Economic and Financial Impacts of Cancer
- CAR-T cell therapy research
- Immune cells in cancer
- Cancer Treatment and Pharmacology
- Multiple and Secondary Primary Cancers
- Neutropenia and Cancer Infections
- Urinary and Genital Oncology Studies
- Cancer survivorship and care
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- DNA and Nucleic Acid Chemistry
- Renal Diseases and Glomerulopathies
- MicroRNA in disease regulation
- Colorectal Cancer Treatments and Studies
- Photochemistry and Electron Transfer Studies
- Cancer, Hypoxia, and Metabolism
Tampa General Hospital
2019-2025
University of South Florida
2013-2024
Moffitt Cancer Center
2013-2023
Riverview Medical Center
2019
University of Tampa
2014-2018
The University of Texas MD Anderson Cancer Center
2011-2017
The Ohio State University
2017
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2017
St. Jude Children's Research Hospital
2017
University of Alabama at Birmingham
2017
The data reported herein were accepted for assessment by the US Food and Drug Administration Biologics License Application under priority review to establish clinical benefit of durvalumab as second-line therapy locally advanced or metastatic urothelial carcinoma (UC), resulting in its recent approval.To report a planned update safety efficacy patients with advanced/metastatic UC.This is an ongoing phase 1/2 open-label study 191 adult histologically cytologically confirmed UC whose disease...
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations the clinical management of patients with clear cell and non–clear renal carcinoma. These guidelines are developed by a panel leading experts from Member Institutions consisting medical oncologists, hematologists hematologic radiation urologists, pathologists. in continuous evolution updated annually or sometimes more often, if new high-quality data become available interim.
Abstract Abnormal dendritic cell differentiation and accumulation of immature myeloid suppressor cells (ImC) is one the major mechanisms tumor escape. We tested possibility pharmacologic regulation using all-trans-retinoic acid (ATRA). Eighteen patients with metastatic renal carcinoma were treated ATRA followed by s.c. interleukin 2 (IL-2). Eight healthy individuals comprised a control group. As expected, cancer had substantially elevated levels ImC. observed that dramatically reduced number...
In 2008, an estimated 54,390 Americans were diagnosed with kidney cancer and 13,010 died of the disease in United States. 1 Renal cell carcinoma (RCC) comprises approximately 2% all malignancies, a median age at diagnosis 65 years.The rate RCC has increased per year for past reason this increase is unknown.Approximately 90% renal tumors are RCC, 85% these clear tumors. 2Other, less-common types include papillary, chromophobe, Bellini (collecting) duct tumors.Collecting fewer than 1%...
Abstract Myeloid-derived suppressor cells (MDSC) play an important role in tumor escape by suppressing T-cell responses. MDSC represent a group of myeloid lineage at different stages differentiation. Increased arginase activity and production reactive oxygen species (ROS) are among the main functional characteristics these cells. Recent studies have shown that all-trans retinoic acid (ATRA) had potent eliminating cancer patients tumor-bearing mice. ATRA differentiates into mature However,...
Abstract Purpose: Nivolumab, an anti-PD-1 immune checkpoint inhibitor, improved overall survival versus everolimus in a phase 3 trial of previously treated patients with metastatic renal cell carcinoma (mRCC). We investigated immunomodulatory activity nivolumab hypothesis-generating prospective mRCC trial. Experimental Design: Nivolumab was administered intravenously every weeks at 0.3, 2, or 10 mg/kg to and treatment-naïve mRCC. Baseline on-treatment biopsies blood were obtained. Clinical...
Myeloid-derived suppressor cells (MDSC) are one of the major factors responsible for immune suppression in cancer. Therefore, it would be important to identify effective therapeutic means modulate these cells.We evaluated effect synthetic triterpenoid C-28 methyl ester 2-cyano-3,12-dioxooleana-1,9,-dien-28-oic acid (CDDO-Me; bardoxolone methyl) MC38 colon carcinoma, Lewis lung and EL-4 thymoma mouse tumor models, as well blood samples from patients with renal cell cancer soft tissue sarcoma....
Men receiving androgen-deprivation therapy (ADT) for prostate cancer may be at risk cognitive impairment; however, evidence is mixed in the existing literature. Our study examined impact of ADT on impaired performance and explored potential demographic genetic predictors performance.Patients with were assessed before or within 21 days starting (n = 58) 6 12 months later. Age- education-matched patients treated prostatectomy only 84) men without 88) similar intervals. Participants provided...
To determine the safety, toxicity, and maximum-tolerated dose of a sequence-specific combination histone deacetylase inhibitor (HDACi), valproic acid (VPA), epirubicin in solid tumor malignancies to define clinical feasibility VPA as an HDACi.Patients were treated with increasing doses (days 1 through 3) followed by (day 3-week cycles. The study evaluated pharmacokinetic pharmacodynamic end points, toxicities, response.Forty-eight patients enrolled, 44 received at least one cycle therapy....
Neoadjuvant chemotherapy (NAC) followed by radical cystectomy improves survival compared with alone for patients bladder cancer. Although gemcitabine cisplatin has become a standard NAC regimen, dose-dense combination of methotrexate, vinblastine, doxorubicin, and (ddMVAC) is being adopted at some institutions.To assess the association neoadjuvant ddMVAC vs regimens downstaging overall among treated cancer.Cross-sectional analysis data extracted from medical records consecutive sample, after...
<h3>Background</h3> Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond further therapies needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in a subset of mM mRCC patients. The efficacy toxicity HD IL-2 therapy following or anti-PD-L1 have yet been explored. <h3>Methods</h3> Reports on who had received after PD-1 PD-L1 inhibition were queried from the PROCLAIM<sup>SM</sup> database....
Abstract Purpose: The antisense oligonucleotide LY2275796 blocks expression of cap-binding protein eukaryotic initiation factor 4E (eIF-4E), an mRNA translation regulator upregulated in tumors. This phase I study sought appropriate dose patients with advanced Experimental Design: A 3-day loading dose, then weekly maintenance doses, were given to 1 3 patient cohorts, beginning 100 mg and escalating. Plasma samples collected determine concentrations tumor biopsies quantify eIF-4E mRNA/protein....
It remains unclear how localized radiotherapy for cancer metastases can occasionally elicit a systemic antitumor effect, known as the abscopal but historically, it has been speculated to reflect generation of host immunotherapeutic response. The ability purposefully and reliably induce effects in metastatic tumors could meet many unmet clinical needs. Here, we describe mathematical model that incorporates physiologic information about T-cell trafficking estimate distribution focal...
High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and melanoma (mM) 1998, an era predating targeted therapies immune checkpoint inhibitors. The PROCLAIMSM registry established to collect analyze data patients treated with HD IL-2 the current era. This analysis includes 170 mM 192 mRCC between 2005 2012 survival as July 27, 2015. For mM, complete response (CR) observed 5 %, partial (PR) 10 stable disease (SD) 22 63 % had progressive...
Non-clear cell renal carcinoma (nccRCC) accounts for ≤20% of RCC cases. Lenvatinib (a multitargeted tyrosine kinase inhibitor) in combination with everolimus (an mTOR is approved the treatment advanced after one prior antiangiogenic therapy.To determine safety and efficacy lenvatinib plus as a first-line patients nccRCC.This open-label, single-arm, multicenter, phase 2 study enrolled unresectable or metastatic nccRCC no anticancer therapy disease.Lenvatinib (18 mg) (5 orally once daily.The...
Abstract BACKGROUND: This study evaluated the tolerability and antitumor activity of AMG 386, a peptibody (a peptide Fc fusion) that neutralizes interaction angiopoietin‐1 angiopoietin‐2 with Tie2 (tyrosine kinase immunoglobulin‐like EGF‐like domains 2), plus sorafenib in patients clear cell metastatic renal carcinoma (mRCC) randomized controlled study. METHODS: Previously untreated mRCC were 1:1:1 to receive 400 mg orally twice daily intravenous 386 at 10 mg/kg (arm A) or 3 B) placebo C)...
Abstract Functionally altered myeloid cells play an important role in immune suppression cancer, angiogenesis, and tumor cells' invasion metastases. Here, we report that inhibition of Notch signaling hematopoietic progenitor (HPC), myeloid-derived suppressor (MDSC), dendritic is directly involved abnormal cell differentiation cancer. Inhibition was caused by the disruption interaction between receptor transcriptional repressor CSL, which normally required for efficient transcription target...
Objective Prostate cancer patients who receive androgen deprivation therapy (ADT) often experience many physical and psychological side effects. ADT may be associated with increased risk for depression, but the relationship between depression is not fully understood. This study used a longitudinal design to assess depressive symptomatology in receiving compared two groups of matched controls. Methods Participants were men initiating treatment (ADT+ group; n = 61) their controls: prostate...